iShares Nasdaq US Biotechnology/£BTEK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About BTEK ETF
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements.
Ticker
£BTEK
Fund name
iShares Nasdaq US Biotechnology
Primary listing
LSE
Fund Manager
Share currency
Benchmark
NASDAQ Biotechnology Index (Net Total Return)
Base currency
USD
Risk
6
BTEK Metrics
£677M
-
BTEK Fund Highlights
This fund aims to track the Nasdaq Biotechnology index, which covers Nasdaq listed companies primarily engaged in biomedical research to develop new treatments and cures for human disease.
4.72%
Accumulating
0.35%
2.10%
0.03%
BTEK Fund Breakdown
Gilead Sciences
7.49%
Amgen
7.16%
Vertex Pharmaceuticals
7.10%
Regeneron
6.08%
Alnylam Pharmaceuticals
3.43%
Insmed
2.45%
Revolution Medicines
2.34%
Biogen
2.06%
United Therapeutics
1.96%
Other
59.93%
Other funds tracking NASDAQ Biotechnology Index (Net Total Return)
Fund name
Fund size
Annual fund charges
iShares Nasdaq US Biotechnology
$BTEC·Acc·USD
$915M
0.35%
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk